PhRMA: Market overreacted to Obama plans

In another layer of support for President Obama's healthcare reform plans, PhRMA chief Billy Tauzin said drug companies won't lose even if universal healthcare ends up depressing pharma prices. That's because drugmakers would sell more of the lower-priced meds, making up in volume what they lose on price cuts. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.